Abstract:BACKGROUND: In recent years, the discovery that bone marrow stromal cells (BMSCs) have the potential of multi-differentiation, especially the successful differentiation of BMSCs to neural stem cells (NSCs), has provided possibility for cell transplantation in treating injury of nervous system. OBJECTIVE: To observe the therapeutic effect of the aurotransplantation of BMSCs-derived stem cells on brain injury. DESIGN: A prospective study by taking the distribution of BrdU labeled autologous BMSCs-derived stem cells in the damaged and other brain areas of animal models as the observational object. MATERIALS: The experiments were carried out in the General Hospital of Beijing Military Area Command of Chinese PLA from October 1999 to February 2002. Twenty-two adult dogs of 1.5-3.0 years old, either males or females, weighing (13±2) kg, were randomly divided into sham-operated group (n=6), routine treatment group (n=8) and BMSCs-derived stem cells group (n=8). METHODS: Dog BMSCs were collected proliferated, separated, pre-differentiated in vitro, marked and cultured. In the sham-operated group, the dogs were only treated with skin incision and skull drilling, but not induced to midbrain injury, and they could eat normally after became conscious from anesthesia. After lesion of midbrain tagmental area, in the routine treatment group, adenosine triphosphate (20 mg) and coenzyme A (50 u) were added to salineand then dripped via vein, twice a day for 3 days; In the BMSCs-derived NSCs group, the mixture of 1 mL BMSCs-derived NSCs and 1 mL cerebrospinal fluid was infused into the brain ventricle, once a day for 3 days continuously. The distribution of BMSCs-derived stem cells in the damaged and other brain areas was observed on the 1st, 7th, 14th and 28th days postoperatively. MAIN OUTCOME MEASURES: The distribution of BMSCs-derived stem cells in the damaged and other brain areas was observed. RESULTS: All the 22 dogs were involved in the analysis of results. ① On the 28th day postoperatively, the number of BrdU positive cells in the BMSCs-derived NSCs group was obviously higher than those in the sham-operated group and routine treatment group (15.4±2.4), (0.5±0.5), (0.5±0.5) cells. ② On the 14th day postoperatively in the BMSCs-derived NSCs group, the number of BrdU positive cells in ipsilateral midbrain was obviously higher than that in the contralateral one (15.5±3.3), (5.0±1.5) cells, and that in the ipsilateral frontal lobe was higher than that in the contralateral one (1.6±0.6), (1.5±0.7) cells. CONCLUSION: The number of BrdU positive cells in the damaged area of the BMSCs-derived NSCs group was obviously more than that in the contralateral areas and those in the same sites of the other two groups, it is indicated that BMSCs-derived stem cells can immigrate to the damaged brain area, and they can accelerate the recovery of brain stem injuries.

A Comparison of Autologous and Allogenic Bone Marrow-Derived Mesenchymal Stem Cell Transplantation in Canine Spinal Cord Injury.

An In Vitro Comparison of the Neurotrophic and Angiogenic Activity of Human and Canine Adipose-Derived Mesenchymal Stem Cells (MSCs): Translating MSC-Based Therapies for Spinal Cord Injury

A comparison of neurosphere differentiation potential of canine bone marrow-derived mesenchymal stem cells and adipose-derived mesenchymal stem cells

The Long-Term Efficacy Study of Multiple Allogeneic Canine Adipose Tissue-Derived Mesenchymal Stem Cells Transplantations Combined With Surgery in Four Dogs With Lumbosacral Spinal Cord Injury

Recovery of Paralyzed Limb Motor Function in Canine with Complete Spinal Cord Injury Following Implantation of MSC-derived Neural Network Tissue.

Transplantation of Mesenchymal Stem Cells for Acute Spinal Cord Injury in Rats: Comparative Study between Intralesional Injection and Scaffold Based Transplantation

Allotransplantation of adult spinal cord tissues after complete transected spinal cord injury: Long-term survival and functional recovery in canines

Distribution of autologous bone marrow stromal cell derived stem cells in damaged and other brain regions

Experimental study and short-term clinical follow-up of bone mesenchymal stem cells transplantation for repair of spinal cord injury

Transplantation of mesenchymal stem cells for spinal cord injury: a systematic review and network meta-analysis

Mesenchymal Stem Cells for the Treatment of Spinal Cord Injury in Rat Models: A Systematic Review and Network Meta-Analysis

The Empirical Study on the Repair of Spinal Cord Injury by Transplantation of Autogeneic Mesenchymal Stem Cells and Electro-Stimulant Therapy

[Analysis of Chronergy for Treatment of Spinal Cord Injury with the Allogeneic Bone Mesenchymal Stem Cells (bmscs) Transplantation in Rats].

Transplantation of hUC-MSCs seeded collagen scaffolds reduces scar formation and promotes functional recovery in canines with chronic spinal cord injury

Transplantation of autologous bone marrow mesenchymal stem cells in the treatment of complete and chronic cervical spinal cord injury

Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Therapy Promotes Functional Recovery of Contused Rat Spinal Cord through Enhancement of Endogenous Cell Proliferation and Oligogenesis

Collagen/heparin sulfate scaffold combined with mesenchymal stem cells treatment for canines with spinal cord injury: A pilot feasibility study

Comparison of Neural Stem Cells and Bone Marrow Mesenchymal Stem Cells Transplantation for Spinal Cord Injury

Influential factors on stem cell therapy success in canine model of spinal cord Injury: A systematic review and meta-analysis

Heat-Shock Proteins Can Potentiate the Therapeutic Ability of Cryopreserved Mesenchymal Stem Cells for the Treatment of Acute Spinal Cord Injury in Dogs

Functional Recovery and Microenvironmental Alterations in A Rat Model of Spinal Cord Injury Following Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Transplantation